Institutional Investors Control 71% of Avidity Biosciences, Inc. (NASDAQ:RNA) and Were Rewarded Last Week After Stock Increased 11%
Institutional Investors Control 71% of Avidity Biosciences, Inc. (NASDAQ:RNA) and Were Rewarded Last Week After Stock Increased 11%
Key Insights
主要見解
- Significantly high institutional ownership implies Avidity Biosciences' stock price is sensitive to their trading actions
- A total of 8 investors have a majority stake in the company with 52% ownership
- Insiders have sold recently
- 機構投資者佔比高意味着Avidity Biosciences的股價對其交易行動非常敏感。
- 總共有8個投資者擁有該公司的52%所有權。
- 近期內有內部人士出售股票
If you want to know who really controls Avidity Biosciences, Inc. (NASDAQ:RNA), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 71% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想了解誰真正控制着Avidity Biosciences,Inc. (納斯達克:RNA),那麼你必須看看它的股東名冊。我們發現機構持有公司的大部分股份,以71%的比例。換句話說,該集團面臨着最大的上行潛力(或下行風險)。
And last week, institutional investors ended up benefitting the most after the company hit US$5.2b in market cap. One-year return to shareholders is currently 435% and last week's gain was the icing on the cake.
上週,機構投資者在該公司市值達到52億美元后獲得了最大的收益。 股東的一年回報率目前爲435%,而上週的收益則是錦上添花。
Let's take a closer look to see what the different types of shareholders can tell us about Avidity Biosciences.
讓我們更仔細地看一看Avidity Biosciences的不同股東類型,了解他們對公司的貢獻。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240812/0-e1014b1673288f8c945314bdf2d58219-0-a81d296024144d47e8b73ae3aa7085d1.png/big)
What Does The Institutional Ownership Tell Us About Avidity Biosciences?
機構投資者的持股情況給Avidity Biosciences帶來了什麼信息?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
We can see that Avidity Biosciences does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Avidity Biosciences' historic earnings and revenue below, but keep in mind there's always more to the story.
我們發現Avidity Biosciences確實擁有機構投資者,並且他們持有公司的大部分股份。這表明專業投資者對公司有一定的信譽。但我們不能僅依靠這一事實,因爲機構有時會做出糟糕的投資決策,就像其他人一樣。當多個機構持有股票時,總有一種可能是它們處於一種「擁擠的交易」中。當這樣的交易出現問題時,多個參與方可能會競相快速賣出股票。在一個沒有增長曆史的公司中,這種風險更高。您可以查看Avidity Biosciences的歷史收益和營業收入,但請記住,故事總是更爲複雜的。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240812/0-e1014b1673288f8c945314bdf2d58219-1-2c06e6f7751ad4b5571e28eb2f38c912.png/big)
Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Avidity Biosciences shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. FMR LLC is currently the company's largest shareholder with 13% of shares outstanding. In comparison, the second and third largest shareholders hold about 7.3% and 6.8% of the stock.
由於機構投資者持有的已發行股份超過一半,董事會可能會注意他們的表態。看起來Avidity Biosciences的股份的13%由對沖基金控制。這引起了我的關注,因爲對沖基金有時會試圖影響管理或帶來會爲股東創造短期價值的變化。FMR LLC目前是該公司持有的最大股東,持有13%的流通股。相比之下,第二和第三大股東持有約7.3%和6.8%的股票。
We did some more digging and found that 8 of the top shareholders account for roughly 52% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
我們進一步挖掘發現,前8大股東佔該公司註冊股份的約52%,這意味着除了大股東之外,還有少數小股東,這樣可以在一定程度上平衡彼此的利益。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
研究機構持股比例是衡量和篩選股票預期表現的好方法。同樣可以通過研究分析師情緒來實現。由於相當多的分析師都關注着該股票,因此你可以很容易地研究預測的增長。
Insider Ownership Of Avidity Biosciences
Avidity Biosciences的內部股權
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
雖然內部人員的精確定義可能具有主觀性,但幾乎所有人都認爲董事會成員是內部人員。管理層最終向董事會負責。然而,如果經理是創始人或CEO,那麼他們成爲執行董事會成員並不罕見。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
Our most recent data indicates that insiders own less than 1% of Avidity Biosciences, Inc.. Keep in mind that it's a big company, and the insiders own US$21m worth of shares. The absolute value might be more important than the proportional share. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我們最近的數據顯示,內部人士擁有Avidity Biosciences股份不到1%。請記住,這是一家大公司,內部人士擁有價值2100萬美元的股份。絕對價值可能比比例份額更重要。看到至少有一些內部所有權總是件好事,但可能值得檢查這些內部所有者是否已經出售股份。
General Public Ownership
一般大衆所有權
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Avidity Biosciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
擁有11%的公衆股東(主要是個人投資者),對Avidity Biosciences有一定的影響力。儘管持股比例相當大,但如果決策與其他大股東不一致,可能無法改變公司政策。
Public Company Ownership
上市公司所有權
It appears to us that public companies own 4.6% of Avidity Biosciences. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
我們認爲公共公司擁有Avidity Biosciences的股份約爲4.6%。這很難確定,但這表明他們存在相互交織的業務利益。這可能是一種戰略性的利益,因此值得密切關注所有權的變化。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 4 warning signs for Avidity Biosciences you should know about.
雖然考慮到擁有一家公司的不同持股集團非常重要,但還有其他更重要的因素。例如,風險。每個公司都有風險,我們發現Avidity Biosciences存在4個警示信號,你應該知道。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果您希望了解分析師在未來增長方面的預測,請務必不要錯過這份免費報告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。